Peripheral Arterial disease (PAD) is an occlusion of the peripheral arteries and is widely viewed as a measure of an individual's global systemic atherosclerotic burden. Typically, it is defined as an ankle-brachial pressure index (APBI) ratio of <0.9. PAD can also be known as peripheral arterial occlusive disease, arteriosclerosis obliterans, lower extremity occlusive disease and peripheral vascular disease.

This report provides the current prevalent population for PAD across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Sweden, Greece, Russia, Turkey, Saudi Arabia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main patient features and co-morbidities of PAD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PAD include:

  • Hypertension
  • Family history of PAD
  • Dyslipidaemia
  • Obesity
  • Diabetes
  • Lower limb ischaemia
  • Myocardial infarction
  • Coronary artery disease (CAD)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global PAD market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of PAD and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding on the impact of specific co-morbid conditions on the prevalent population of PAD patients.
  • Identification of PAD patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of PAD patients.